U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C22H32N2O6.2ClH
Molecular Weight 493.421
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEXOPRENALINE DIHYDROCHLORIDE

SMILES

Cl.Cl.OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C2=CC=C(O)C(O)=C2

InChI

InChIKey=LECFJMMCVCBLPN-UHFFFAOYSA-N
InChI=1S/C22H32N2O6.2ClH/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16;;/h5-8,11-12,21-30H,1-4,9-10,13-14H2;2*1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H32N2O6
Molecular Weight 420.4993
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html

Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
GYNIPRAL

Approved Use

Gynipral prevents threatened abortion with premature labour.
PubMed

PubMed

TitleDatePubMed
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison].
1983 Mar
A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents.
1985 Oct
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001
[Comparison of the cost of treatment of premature labor with atosiban or beta-sympathomimetics from the perspective of the health care payer--a pharmacoeconomic model].
2004 Mar
Beta 2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats.
2004 Sep
Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation.
2009 Jun 19
Management of foetal asphyxia by intrauterine foetal resuscitation.
2010 Sep

Sample Use Guides

In Vivo Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/195789
Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:50:46 GMT 2023
Edited
by admin
on Sat Dec 16 07:50:46 GMT 2023
Record UNII
97TDI0239I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEXOPRENALINE DIHYDROCHLORIDE
MI  
Common Name English
Hexoprenaline hydrochloride [WHO-DD]
Common Name English
HEXOPRENALINE HYDROCHLORIDE
WHO-DD  
Common Name English
HEXOPRENALINE HCL
Common Name English
HEXOPRENALINE DIHYDROCHLORIDE [MI]
Common Name English
BENZYL ALCOHOL, .ALPHA.,.ALPHA.'-(HEXAMETHYLENEBIS(IMINOMETHYLENE))BIS(3,4-DIHYDROXY-, DIHYDROCHLORIDE
Common Name English
Code System Code Type Description
SMS_ID
100000128147
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY
CAS
4323-43-7
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY
PUBCHEM
20321
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID60962973
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY
ECHA (EC/EINECS)
224-354-2
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY
FDA UNII
97TDI0239I
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY
EVMPD
SUB34902
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY
MERCK INDEX
m6013
Created by admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY